Psychedelic-assisted therapy as an evidence-based approach: are we there yet?
For several decades, studies with classical psychedelics have been significantly hampered by their legal status. Recently, researchers have begun to re-examine their therapeutic value launching a number of new small-scale studies, which have provided a substantial body of evidence for their efficacy and acceptable safety profile in the treatment of several psychiatric conditions such as depression, anxiety disorders and addictions.
What are the mechanisms of action of these substances? What makes them special in comparison to other psychoactive drugs? Finally, what is the context, indications and contraindications for psychedelic-assisted therapy? Can we call it an "evidence-based approach"? These and other related questions will be the topic of discussion in the present event.
We begin with a lecture by Dr. Alexander Lebedev who is a psychiatrist and assistant professor at Karolinska Institutet. As a part of his work, he has collaborated with the Psychedelic Research Group at Imperial College London, which resulted in two publications. He will give an overview of the ongoing research in the field of psychedelic-assisted therapy and summarize recent findings concerning its safety and efficacy.
The following specialists will also join the panel discussion
Predrag Petrovic, MD PhD
Psychiatrist, and experienced researcher investigating mechanisms underlying placebo effects and high-order cognition in clinical and non-clinical populations. Author of several popular books on cognitive neuropsychology. His research is primarily focused on how expectations influence our perception and subsequently formed beliefs.
Åsa Nilsonne, MD PhD
Professor Emeritus in Medical Psychology at Karolinska Institutet. Psychiatrist, psychotherapist and writer. Author of several books on mindfulness and psychotherapy, as well as the recently published professional biography “Processen - möten, mediciner, beslut”. Åsa holds a particular interest in integrating perspectives from psychology and pharmacology.
Andreas Åberg, MD
Specialist and senior physician in psychiatry at Sundsvall Hospital. Consultant Doctor and Managing Director of Levante Psychiatry. Andreas has a particular interest in the use of MDMA in the treatment of Post-Traumatic Stress Disorder (PTSD).
The panel discussion will be moderated by Jonas Mattsson, editor of Modern Psykologi
The event is free of charge and no registration is required. Seats are however limited; it is advised to arrive early to secure a seat.Contact person: Alexander Lebedev